Abiopharma

🔍 Behbahani Ali (Executive)

Company: Black Diamond Therapeutics, Inc. (BDTX)

Report Date: 2025-12-12

Detailed Transactions and Holdings:

• Acquired 5,208 shares of Common Stock at $2.76 per share (Direct)
  Date: 2025-12-12 | Code: A | equity_swap_involved: false | shares_owned_after: 86,649.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-12 | Code: H | nature_of_ownership: See Note 3 | shares_owned_after: 4,448,757.00 | Footnotes: F3

Footnotes:

• F1: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
• F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025.
• F3: The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.